AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14511275
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg dose of eletriptan
Trial: 10811333
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum (DSM 9843) in a rose-hip drink (400 ml per day, 5 x 10(7) cfu/ml)
Trial: 8644026
Drug: Neoton infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoton infusions (30 g/day for 3 days)
Trial: 8644026
Drug: Emoxipin injected
RxNorm normalized name: Emoxipin
DrugBank: Emoxypine (DB19172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emoxipin injected intramuscularly (3 mg/kg for 20 days)
Trial: 8644026
Drug: Emoxipin injected
RxNorm normalized name: Emoxipin
DrugBank: Emoxypine (DB19172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emoxipin injected intravenously (10 mg/kg)
Trial: 1352245
Drug: xamoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol (200 mg b.i.d. for 7 days)
Trial: 30696041
Drug: MicroLactin® (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MicroLactin® (ML)
Trial: 19755572
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg single dose)
Trial: 21770829
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (Group A)
Trial: 21770829
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no melatonin treatment, Group B)
Trial: 21147712
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron and 0.4 mg folic acid
Trial: 21147712
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron, 2.0 mg retinol and 0.4 mg folic acid
Trial: 16844502
Drug: Retinyl N‐formyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl N‐formyl aspartamate applied twice daily on the left half of the face
Trial: 14708457
Drug: Clinidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinidipine (10 mg)
Trial: 12441222
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 mg)
Trial: 11185412
Drug: Gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 320 mg in fasted state
Trial: 11185412
Drug: Gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 320 mg after a high fat meal
Trial: 11185412
Drug: Gemifloxacin 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 640 mg in fasted state
Trial: 11185412
Drug: Gemifloxacin 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 640 mg after a high fat meal
Trial: 1562720
Drug: Consolidation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation therapy (6 days of high-dose cytarabine plus 3 days of amsacrine)
Trial: 1562720
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (2 years of continuous outpatient therapy with cytarabine and 6-thioguanine)
Trial: 31601494
Drug: Ketorolac (15-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (15-mg IV every 6 hours)
Trial: 31601494
Drug: Acetaminophen (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1-g IV every 6 hours)
Trial: 29023185
Drug: Low-Intensity Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Laser Therapy (LLLT) - InGaAlP, λ 660 nm, energy density 6 J/cm2, applied daily from the first to the fourth postoperative day.
Trial: 26660143
Drug: Secukinumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (monthly regimen, baseline, weeks 4, 8)
Trial: 16585986
Drug: 0.3% Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% Tacrolimus gel
Trial: 16585986
Drug: 0.5% Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Tacrolimus cream
Trial: 16585986
Drug: Tacrolimus gel
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus gel and cream
Trial: 14644852
Drug: Paracetamol recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol recommended
Trial: 8834029
Drug: Octreotide (100-micrograms/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100-micrograms/h infusion after a 100-micrograms bolus)
Trial: 1410154
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum (first dose)
Trial: 1410154
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum (second and third doses)
Trial: 3907259
Drug: Atropine eye
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine eye drops applied twice a day for 3.5 days
Trial: 30219459
Drug: Sunlight exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunlight exposure with vitamin D supplementation (20,000 IU weekly)
Trial: 22497677
Drug: bisoprolol 10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol 10 mg/day
Trial: 18325025
Drug: Citicoline (Cebrolux-Tubilux,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (Cebrolux-Tubilux, Italy, 1600 mg/diem for 60 days)
Trial: 16091759
Drug: sequential methotrexate‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential methotrexate‐fluorouracil (MF)
Trial: 12360462
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (beta-blockers and nitrates)
Trial: 8708716
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (40 mg/m2) added to high-dose infusional 5-FU (60 mg/kg over 48 hours) given weekly for 4 weeks and thereafter every 2 and 3 weeks.
Trial: 8708716
Drug: High-dose infusional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose infusional 5-FU without low-dose methotrexate.
Trial: 8708716
Drug: High-dose infusional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose infusional 5-FU with low-dose methotrexate.
Trial: 6756933
Drug: muzolimine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muzolimine (35 +/- 2 mg/day for six weeks)
Trial: 31566689
Drug: Enhanced tablet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced tablet-based book
Trial: 31566689
Drug: Basic tablet-based
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic tablet-based book
Trial: 17139639
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC; exercise therapy and advice)
Trial: 12629448
Drug: Functional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional insulin therapy with short-acting insulin analog
Trial: 8940672
Drug: Podophyllotoxin cream
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin cream 0.15%
Trial: 8940672
Drug: Podophyllotoxin cream
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin cream 0.3%
Trial: 8940672
Drug: Podophyllotoxin solution
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin solution 0.5%
Trial: 8940672
Drug: Podophyllotoxin cream
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin cream 0.15% (female)
Trial: 8940672
Drug: Podophyllotoxin cream
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin cream 0.3% (female)
Trial: 8940672
Drug: Podophyllotoxin solution
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin solution 0.5% (female)
Trial: 1527313
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray 200 micrograms once a day
Trial: 1527313
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice a day
Trial: 3873880
Drug: Metocurine-pancuronium combination
RxNorm normalized name: metocurine
DrugBank: Metocurine (DB01336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metocurine-pancuronium combination (4:1 ratio by weight) (n = 12)
Trial: 27378733
Drug: Home- and
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home- and community-based exercise program (12 weeks, with once-weekly telephone or e-mail support)
Trial: 25637265
Drug: Buspirone (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (a partial 5-HT1A receptor agonist)
Trial: 21138709
Drug: 0.125 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 g/kg alcohol dose
Trial: 9209553
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg alcohol dose
Trial: 21138709
Drug: 0.75 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g/kg alcohol dose
Trial: 9209553
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg alcohol dose
Trial: 14656780
Drug: iv ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv ondansetron 4 mg
Trial: 10195004
Drug: Iodixanol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (600 mgI kg‐1 bw, 320 mgI ml‐1)
Trial: 10195004
Drug: Iopromide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide (600 mgI kg‐1 bw, 300 mgI ml‐1)
Trial: 7846101
Drug: Dietary gamma-linolenic
RxNorm normalized name: gamma-linolenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary gamma-linolenic acid (GLA) at a dose of 3 g/day for humans and 3 mg/kg/day for rats for 4 months
Trial: 7846101
Drug: Dietary gamma-linolenic
RxNorm normalized name: gamma-linolenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary gamma-linolenic acid (GLA) at a dose of 3 mg/kg/day for rats for 4 months
Trial: 21600709
Drug: Occupational Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational Therapy Intervention (OTI)
Trial: 28258815
Drug: Xylazine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine (200 μg kg−1)
Trial: 28258815
Drug: Dexmedetomidine (0.875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.875 μg kg−1)
Trial: 25635959
Drug: Occlusal appliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal appliance therapy (OA)
Trial: 19506455
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy with concurrent low-dose daily platinum chemotherapy
Trial: 19506455
Drug: Standard fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fraction (conventionally fractionated) radiation therapy
Trial: 19506455
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy without concurrent chemotherapy
Trial: 19506455
Drug: Treatment (general)
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (general)
Trial: 9457819
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CHT)
Trial: 17075912
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus 10 sessions of twice‐weekly prolonged exposure (PE)
Trial: 11709564
Drug: Aminoglutethimide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (250 mg daily) for 2 years
Trial: 8181847
Drug: Ciprofloxacin, 250
RxNorm normalized name: Ciprofloxacin, 250 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 250 mg twice daily
Trial: 8181847
Drug: Ofloxacin, 200
RxNorm normalized name: Ofloxacin, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin, 200 mg twice daily
Trial: 31471001
Drug: Website with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Website with vaccine information and interactive social media components
Trial: 31471001
Drug: Website with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Website with vaccine information only
Trial: 27278272
Drug: Grade 3/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 3/4 Chemotherapy-Induced Neutropenia (CIN)
Trial: 27278272
Drug: Grade 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 4 Chemotherapy-Induced Neutropenia (CIN)
Trial: 18794494
Drug: CTLA4Ig infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTLA4Ig infusion
Trial: 8954018
Drug: NOMA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOMA (5 mg/day)
Trial: 8954018
Drug: NETA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETA (10 mg/day)
Trial: 8954018
Drug: NOMA +
RxNorm normalized name: Nomacopan
DrugBank: Nomacopan (DB14991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOMA + FLU (250 mg, twice a day)
Trial: 8954018
Drug: NETA +
RxNorm normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NETA + FLU (250 mg, twice a day)
Trial: 1935866
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus oral Valium
Trial: 31321805
Drug: Consolidative allogeneic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT) within three months after CAR-T therapy for MRD-CR patients.
Trial: 31321805
Drug: CAR-T therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T therapy without subsequent allo-HSCT.
Trial: 27883172
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate and a high calorie supplement (2108‐2416 kJ/day)
Trial: 27883172
Drug: Placebo testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo testosterone and low calorie supplement (142‐191 kJ/day)
Trial: 23017325
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin (81 mg) and EPA+DHA (3.4 g/d)
Trial: 23017325
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg) alone
Trial: 23017325
Drug: EPA+DHA (3.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA (3.4 g/d) alone
Trial: 20401350
Drug: GanedenBC(30) -
RxNorm normalized name: Ganedenbc 30
DrugBank: Bacillus coagulans (DB19246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GanedenBC(30) - 1 capsule/day for 28 days
Trial: 16132930
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate treatment
Trial: 12181623
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg per os daily
Trial: 12181623
Drug: Clodronate 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 100 mg intramuscularly every 10 days
Trial: 30636771
Drug: Formula supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula supplemented with 65 mg/L bOPN (F65)
Trial: 30636771
Drug: Formula supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula supplemented with 130 mg/L bOPN (F130)
Trial: 26740639
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) - 30 daily sessions of 90 min at 244 kPa
Trial: 26740639
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment - 30 daily sessions of 90 min breathing air at 125 kPa
Trial: 25108448
Drug: Overall comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall comparison of early vs deferred treatment
Trial: 19902033
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa oil 2.5 ml twice daily, atorvastatin 10 mg once a day, metformin 500 mg twice a day for 6 weeks
Trial: 19902033
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg once a day, metformin 500 mg twice a day for 6 weeks
Trial: 15830199
Drug: A3 adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A3 adenosine receptor expression in PEX eyes
Trial: 1599984
Drug: Amitriptyline combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline combined with a low dose of flupentixol
Trial: 3902326
Drug: Iodine concentration
RxNorm normalized name: iodine Topical Solution [QuarterMate Concentrate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine concentration higher than 370 mgI/ml
Trial: 3902326
Drug: Iodine concentration
RxNorm normalized name: iodine Topical Solution [QuarterMate Concentrate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine concentration 370 mgI/ml or lower
Trial: 28976895
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg acetylsalicylic acid (ASA) continued
Trial: 28976895
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg acetylsalicylic acid (ASA) stopped 72 hours before extraction
Trial: 28976895
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel continued
Trial: 28976895
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel stopped 72 hours before extraction
Trial: 15871196
Drug: 0.375% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% hyperbaric bupivacaine solutions
Trial: 15871196
Drug: 0.375% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% isobaric bupivacaine solutions
Trial: 15871196
Drug: 0.375% hypobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% hypobaric bupivacaine solutions
Trial: 12411141
Drug: Lung protective
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung protective group (n = 34) perfused with hypothermic protective solution to the pulmonary artery
Trial: 28336740
Drug: Without intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Without intra-arterial treatment (IAT)
Trial: 19453310
Drug: Dopexamine treatment
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine treatment
Trial: 14699486
Drug: Glucagon (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (bolus of 4.8 microg/kg plus infusion of 9.6 microg x kg(‐1) x h(‐1)) at high intragastric volume (75% of threshold volume for discomfort)
Trial: 14699486
Drug: Erythromycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3 mg/kg) at high intragastric volume
Trial: 14699486
Drug: Erythromycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3 mg/kg) at low intragastric volume (perception threshold)
Trial: 12439364
Drug: Fenoldopam (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (a selective dopamine receptor agonist) used as an adjunct during PCI for prevention of radiocontrast nephropathy (RCN)
Trial: 8007592
Drug: Cyclosporine therapy
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine therapy with physiological infusion of vasopressin
Trial: 373073
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg trimipramine
Trial: 31099085
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU vitamin D3 + 2000 mg calcium/d (n = 73)
Trial: 25637380
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (arm A): FEC100 (500, 100, and 500 mg/m(2) for 3 cycles) followed by docetaxel (100 mg/m(2) for 3 cycles)
Trial: 25637380
Drug: Adapted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted treatment (arm B): 2 cycles of FEC100, switch to docetaxel if tumor size decreased by <30% after 2 cycles or <50% after 4 cycles; otherwise, FEC100 for six cycles before surgery